![](https://qtxasset.com/quartz/qcloud5/media/image/Asia%20Skyline.jpg?VersionId=D1z8mhSGFGZGeIyVQRyF2XVT.Or1FpKP)
Fierce Pharma Asia—J&J's Tagrisso challenger; Merck's revised Kelun deal; The next biosecurity frontier
Yuhan's Lazcluze, licensed by Johnson & Johnson, has made history as the first Korea-developed novel cancer drug to be approved by the FDA. Merck has optioned in on one Kelun Biotech antibody-drug conjugate but returned another. A few U.S. …